Form 4: Vor Biopharma Director David Lubner Receives 30,000 Stock Options

Vor Biopharma Inc. director David Charles Lubner was granted 30,000 stock options with an exercise price of $0.1868 as part of the company's non-employee director compensation policy.

Summary

• David Charles Lubner, a Director of Vor Biopharma Inc. (VOR), was granted 30,000 stock options on May 22, 2025.
• The stock options have an exercise price of $0.1868 per share.
• These options were granted under the Issuer's non-employee director compensation policy.
• The shares underlying the option will vest and become exercisable on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Lubner's continued service as a director through the vesting date.
• The options have an expiration date of May 21, 2035.
• Following this transaction, Mr. Lubner beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine compensation event (stock option grant) to a director. This is a neutral to slightly positive event as it aligns director interests with shareholders, but does not indicate any new operational or financial performance.

Positives

• The grant of stock options aligns the interests of Director David Charles Lubner with those of the shareholders, as the value of the options increases with the company's stock price.
• This is a standard practice for compensating non-employee directors, indicating a structured approach to corporate governance and incentive alignment.

Future Outlook

The future outlook for the granted options is tied to the company's performance and the director's continued service, with vesting scheduled for the earlier of May 22, 2026, or the next annual meeting of stockholders.

Industry Context

The grant of stock options to non-employee directors is a common and widely accepted practice across the biotechnology and broader public company landscape. It serves to attract and retain qualified board members while aligning their financial incentives with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• Compensating non-employee directors with equity, such as stock options, is a standard practice in the biotechnology industry and among publicly traded companies globally. This aligns the director's financial interests with shareholder value creation.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is typical for such grants, ensuring ongoing commitment from board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to David Charles Lubner, a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact mentioned, but a well-governed company with aligned leadership can indirectly benefit all employees.

Next Steps

• The stock options will vest on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders, subject to David Charles Lubner's continued service as a director.
• Upon vesting, the options will become exercisable, allowing Mr. Lubner to purchase common stock at the exercise price of $0.1868.

Key Dates

Keywords

Vor Biopharma, VOR, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, David Charles Lubner, Biopharma